Sanofi-Aventis stock price declines amid management changes and concerns over R&D prospects

Sanofi (SNY.OQ) stock declined on February 12, 2026, primarily due to sudden management changes and market concerns over its R&D prospects.

Leadership Change

On February 12, the company announced that CEO Paul Hudson would step down, with Belén Garijo, a senior executive at Merck Group, taking over in April. This unexpected move was interpreted by the market as the board losing patience with the long-term lack of results from R&D investments. The stock closed down 4.51% at $47.03, hitting a low of $46.71 during the day.

Company Fundamentals

Despite the company reporting a 7% year-over-year revenue increase in Q4 2025 (13.3% at constant exchange rates) and a record €4.246 billion in sales for its core product Dupixent, investors are more concerned about the risks of its R&D pipeline stalling. Over the past 12 months, experimental multiple sclerosis drug tolebrutinib failed in key trials, and the highly anticipated atopic dermatitis candidate amlitelimab showed mixed clinical results. Jefferies reported that management changes could indicate slow progress in R&D transformation.

Performance and Operations

Dupixent accounts for over 30% of the company’s revenue, but its patent is set to expire in the early 2030s, and Sanofi has yet to identify new drugs to replace its revenue. AlphaValue analysts noted that investor patience with repeated R&D failures has worn thin, and leadership changes have increased short-term uncertainty.

Industry Policies and Environment

The vaccine business makes up nearly 20% of revenue but saw a 2.5% year-over-year decline in Q4 sales. The company expects this segment may continue to decline in 2026, as U.S. policy environment issues persist in hindering vaccine promotion. Coupled with the Nasdaq index dropping 2.03% that day, the stock’s decline was amplified.

The above content is compiled from publicly available information and does not constitute investment advice.